IM Cannabis Corp. Stock

Equities

IMCC

CA44969Q3070

Pharmaceuticals

Market Closed - Canadian Securities Exchange 12:25:07 2024-04-25 pm EDT 5-day change 1st Jan Change
0.75 CAD 0.00% Intraday chart for IM Cannabis Corp. -6.25% +63.04%
Sales 2024 * 46.3M 33.9M Sales 2025 * - Capitalization 10.05M 7.35M
Net income 2024 * -10M -7.32M Net income 2025 * - EV / Sales 2024 * 0.22 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees 95
Yield 2024 *
-
Yield 2025 *
-
Free-Float 64.16%
More Fundamentals * Assessed data
Dynamic Chart
IM Cannabis Corp. and Vessel Brand, Inc. Partner to Bring Vessel Cannabis Accessories to the Israeli Market CI
IM Cannabis, Avant Brands Sign BLK MKT's Licensing Deal for German Medical Cannabis Market MT
Transcript : IM Cannabis Corp., 2023 Earnings Call, Mar 28, 2024
IM Cannabis Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IM Cannabis Corp. Brief: Notes This Provides IMC Germany with a "Unique Opportunity" to further accelerate growth in 2024 after delivering 180% growth in 2023 MT
IM Cannabis Corp. Brief: Adds By rescheduling medical cannabis, from a narcotic to a regular prescription, the German medical cannabis market is Expected to deliver "Strong" growth MT
IM Cannabis Corp. Brief: Says Expects "Accelerated Growth" in Germany from that Country's "Groundbreaking" Cannabis Legalization MT
IM Cannabis Corp. Announces German Government's Final Approval of Legalizing Cannabis CI
IMC Announces Potential Reverse Merger With A Leading Clinical Cell Therapy Company MT
Kadimastem Ltd entered into a non-binding term sheet to acquire IM Cannabis Corp. in reverse merger transaction. CI
Avant Brands Brief: Restructuring Loan Agreements to Extend Term and Decrease Payments MT
IM Cannabis Brief: Says Received 180 Calendar Day Extension from Nasdaq Stock Market to Regain Compliance with Bid Price Rule MT
IM Cannabis Rescheduling Final Payment of the Oranim Pharmacy Acquisition MT
IM Cannabis Announced Conclusion of Planning and Construction Legal Proceedings Against Focus Medical MT
IM Cannabis Notes New Israeli Cannabis Regulation Delayed by Three Months MT
More news
1 week-6.25%
Current month+19.05%
1 month+36.36%
3 months+212.50%
6 months-9.64%
Current year+63.04%
More quotes
1 week
0.72
Extreme 0.72
0.86
1 month
0.56
Extreme 0.56
1.78
Current year
0.24
Extreme 0.24
1.78
1 year
0.24
Extreme 0.24
1.90
3 years
0.24
Extreme 0.24
83.10
5 years
0.24
Extreme 0.24
144.00
10 years
0.24
Extreme 0.24
144.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 19-10-10
Director of Finance/CFO 49 23-10-09
- -
Members of the board TitleAgeSince
Director/Board Member - 21-02-21
Chairman 51 19-10-10
Chief Executive Officer 55 19-10-10
More insiders
Date Price Change Volume
24-04-25 0.75 0.00% 2,784
24-04-24 0.75 -1.32% 8,502
24-04-23 0.76 -3.80% 16,562
24-04-22 0.79 -5.95% 14,195
24-04-19 0.84 +5.00% 2,783

Delayed Quote Canadian Securities Exchange, April 25, 2024 at 12:25 pm EDT

More quotes
IM Cannabis Corp. is a Canada-based medical cannabis company. The Company operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), which has a cultivation license to breed, grow and supply medical cannabis products in Israel. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centres and logistical hubs in Israel. The Company operates through Adjupharm GmbH in Europe, which is a medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses granted by German regulatory authorities that allow for import/export capability with requisite permits. The Company operates through Trichome and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.75 CAD
Average target price
3.45 CAD
Spread / Average Target
+360.00%
Consensus

Quarterly revenue - Rate of surprise